logo
Share SHARE
FONT-SIZE Plus   Neg

Amgen Blood Cancer Drug Meets Primary Endpoint In Late-Stage Study

Amgen Inc. (AMGN) Monday said its blood cancer drug Kyprolis in combination with two other drugs helped patients live significantly longer compared to standard treatment.

The California-based drug giant said patients with relapsed multiple myeloma when treated with Kyprolis in combination with Revlimid and low-dose dexamethasone lived 8.7 months longer without disease worsening compared to patients treated with only Revlimid and low-dose dexamethasone.

Multiple myeloma is the second most common hematologic cancer that results from an abnormality of plasma cells, usually in the bone marrow. In the US, about 70,000 people are living with multiple myeloma and around 24,000 new cases are diagnosed annually.

The FDA had granted accelerated approval of Kyprolis for the treatment of patients with multiple myeloma in 2012. Kyprolis is marketed in the US by Amgen's subsidiary Onyx Pharmaceuticals Inc.

The study called Aspire was conducted on 792 patients. Amgen said patients treated with Kyprolis lived for a median of 26.3 months without disease worsening, a significant improvement compared to the 17.6 months in patients who received standard treatment.

Chief Executive Robert Bradway said "Our mission at Amgen is to serve patients by advancing medicines that address serious disease. Kyprolis is an important building block in our robust, differentiated pipeline."

AMGN is currently trading at $126.84, up $1.29 or 1.03%, on the Nasdaq.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Thursday after the markets closed that its second quarter profit fell 21% from last year, hurt by lower revenue and costs related to the planned separation of the company. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Accounting software maker Intuit reported a plunge in third-quarter profit, hurt by impairment charges, even as results topped Wall Street estimates, driven by growth in small business segment amid a strong tax season. Struggling teen-apparel retailer Aeropostale Inc. (ARO), Thursday said its first-quarter loss narrowed from a year ago, driven largely by stronger margins even as revenues continued to plunge dropped. Nevertheless, the company lost almost one-fifth of its market value in after-hours trade, with the...
comments powered by Disqus
RELATED NEWS
Trade AMGN now with 
Follow RTT